The heterogeneity of cancer stem-like cells at the invasive front

Cancer Cell International

Volumn 17, Issue 1, 2017, Pages

  Yoshida, Go J ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

C Myc; Cancer stem like cells; CD44; ESRP1 CD44v xCT axis; Heterogeneity; Invasive front; Minimal residual disease; Negative feedback machinery; Reactive oxygen species; Wnt catenin signal

Indexed keywords

BETA CATENIN; CD44V ANTIGEN; CYSTINE GLUTAMATE TRANSPORTER; GLUTAMATE TRANSPORTER; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN;

ALTERNATIVE RNA SPLICING; ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL HETEROGENEITY; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME LOCALIZATION; HUMAN; NEGATIVE FEEDBACK; NUCLEAR REPROGRAMMING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REDOX STRESS; SIGNAL TRANSDUCTION; STEM CELL NICHE; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 85012951878     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-017-0393-y     Document Type: Article

References (15)

1. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-17.
2. Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci. 2016;107:5-11.
3. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209-13.
4. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150-8.
5. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9.
6. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9-26.
7. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101:9085-90.
8. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254-67.
9. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011;19:387-400.
10. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883.
11. Yoshida GJ, Saya H. Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun. 2014;443:622-7.
12. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell. 2013;23:347-61.
13. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3:1133-7.
14. Funato Y, Michiue T, Asashima M, Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol. 2006;8:501-8.
15. Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.